logo

NTRK Fusion Gene Positive Advanced Solid Tumor Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)

The NTRK Fusion Gene Positive Advanced Solid Tumor market is segmented by Type, by End-User (Hospitals and Clinics, Cancer Centers, Others), and Geography

Home Market Analysis Healthcare Research Medical Devices Research Medical Supplies Research NTRK Fusion Gene Positive Advanced Solid Tumor Market

NTRK Fusion Gene Positive Advanced Solid Tumor Market Size

NFGPAST
Study Period 2019 - 2029
Base Year For Estimation 2023
Forecast Data Period 2024 - 2029
CAGR 5.40 %
Fastest Growing Market Asia Pacific
Largest Market North America

Major Players

NTRK Fusion Gene Positive Advanced Solid Tumor Market

*Disclaimer: Major Players sorted in no particular order

Compare market size and growth of NTRK Fusion Gene Positive Advanced Solid Tumor Market with other markets in Healthcare Industry

Biotechnology

Pharmaceuticals

Healthcare IT

Medical Devices

Animal Health

Device Drug Combination

NTRK Fusion Gene Positive Advanced Solid Tumor Market Analysis

The NTRK Fusion Gene Positive Advanced Solid Tumor market is anticipated to grow with a CAGR of nearly 5.4%, during the forecast period.

Certain factors that are driving the market growth include increasing prevalence of cancer and growing research and development activities. Globally, cancer is one of the leading causes of death. The disease witnessed significant growth in the last few decades, and it is expected to grow rapidly over the forecast period.

The World Health Organization (WHO) estimates the rate of cancer number to increase by 70% over the next two decades. Additionally, the increased burden of several lifestyle disorders is also expected to drive the market, as biomarkers play a vital role in risk assessment, early diagnosis, and effective monitoring of treatment.

FDA's approval of entrectinib for neurotrophic tyrosine receptor kinase (NTRK) fusion-positive tumors represents a new paradigm in cancer treatment. It treats a cancer based on a common biomarker seen across different tumors rather than based on the location in the body where the cancer originated.

NTRK Fusion Gene Positive Advanced Solid Tumor Market Trends

This section covers the major market trends shaping the NTRK Fusion Gene Positive Advanced Solid Tumor Market according to our research experts:

Diagnostics Segment Holds Significant Share in the Global NTRK Fusion Gene Positive Advanced Solid Tumor Market

There are multiple methods for identifying NTRK fusions, including pan-TRK immunohistochemistry, fluorescence in situ hybridization and sequencing methods. FISH and RT-PCR have been successfully used in the clinic to detect NTRK fusions and are reasonable alternatives to NGS, especially for tumor histologies with a high prevalence of NTRK fusions involving recurrent partners (MASC, infantile fibrosarcomas, secretory breast carcinoma, and cellular or mixed congenital mesoblastic nephromas). Recent approvals add to the growth of the segment share. In 2018, SeraCare Life Sciences, a manufacturer and leading partner to global in vitro diagnostics manufacturers and clinical laboratories, launched an expanded neurotrophic tropomyosin receptor kinase (NTRK) RNA fusion reference material panel developed in a partnership with Bayer.

seg nfgpast.PNG

North America Dominates the Global NTRK Fusion Gene Positive Advanced Solid Tumor Market

As per the American Cancer Society, in 2018, the United States witnessed around 164,690 new cases of prostate cancer, causing over 26,430 deaths. About 60% of the total prostate cancer cases diagnosed are among men aged 65 years or older. In order to tackle such challenges, extensive research in the field of diagnostics has been undertaken.

The ease in the US government regulations and availability of funds from various organizations, like the National Institute of Health, have provided the potential for researchers to invest more in the use of fusion genes in drug discovery, drug development, detection of specific tumors, monitoring biological response to cancer therapy, and genetic studies for the identification of predisposed candidates of cancer.

geo nfgpast.PNG

NTRK Fusion Gene Positive Advanced Solid Tumor Industry Overview

The global NTRK Fusion Gene Positive Advanced Solid Tumor market is competitive and consists of a few major players. Companies like Bayer AG, Cephalon, Inc., Empire Genomics, LLC., Exelixis, Inc, F. Hoffmann-La Roche Ltd, NeoGenomics Laboratories, Inc., OncoDNA, among others, hold the substantial market share in the market.

NTRK Fusion Gene Positive Advanced Solid Tumor Market Leaders

  1. Bayer AG

  2. Empire Genomics, LLC

  3. F. Hoffmann-La Roche Ltd.

  4. NeoGenomics Laboratories, Inc.

  5. OncoDNA

*Disclaimer: Major Players sorted in no particular order

comp nfgpast.png
Need More Details on Market Players and Competitors?
Download PDF

NTRK Fusion Gene Positive Advanced Solid Tumor Market Report - Table of Contents

  1. 1. INTRODUCTION

    1. 1.1 Study Deliverables

    2. 1.2 Study Assumptions

    3. 1.3 Scope of the Study

  2. 2. RESEARCH METHODOLOGY

  3. 3. EXECUTIVE SUMMARY

  4. 4. MARKET DYNAMICS

    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Increasing Prevalence of Cancer

      2. 4.2.2 Growing Research and Development Activities

    3. 4.3 Market Restraints

      1. 4.3.1 Poor Healthcare Infrastructure and High Costs associated with Genetic Screening of NTRK Fusion Genes

    4. 4.4 Porter's Five Force Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. MARKET SEGMENTATION

    1. 5.1 By Type

      1. 5.1.1 By Therapeutics

      2. 5.1.2 By Diagnostics

    2. 5.2 By End-User

      1. 5.2.1 Hospitals and Clinics

      2. 5.2.2 Cancer Centers

      3. 5.2.3 Others

    3. 5.3 Geography

      1. 5.3.1 North America

        1. 5.3.1.1 United States

        2. 5.3.1.2 Canada

        3. 5.3.1.3 Mexico

      2. 5.3.2 Europe

        1. 5.3.2.1 Germany

        2. 5.3.2.2 United Kingdom

        3. 5.3.2.3 France

        4. 5.3.2.4 Italy

        5. 5.3.2.5 Spain

        6. 5.3.2.6 Rest of Europe

      3. 5.3.3 Asia-Pacific

        1. 5.3.3.1 China

        2. 5.3.3.2 Japan

        3. 5.3.3.3 India

        4. 5.3.3.4 Australia

        5. 5.3.3.5 South Korea

        6. 5.3.3.6 Rest of Asia-Pacific

      4. 5.3.4 Middle-East and Africa

        1. 5.3.4.1 GCC

        2. 5.3.4.2 South Africa

        3. 5.3.4.3 Rest of Middle-East and Africa

      5. 5.3.5 South America

        1. 5.3.5.1 Brazil

        2. 5.3.5.2 Argentina

        3. 5.3.5.3 Rest of South America

  6. 6. COMPETITIVE LANDSCAPE

    1. 6.1 Company Profiles

      1. 6.1.1 Bayer AG

      2. 6.1.2 Teva Pharmaceuticals

      3. 6.1.3 Empire Genomics, LLC.

      4. 6.1.4 SeraCare Life Sciences

      5. 6.1.5 F. Hoffmann-La Roche Ltd

      6. 6.1.6 NeoGenomics Laboratories, Inc.

      7. 6.1.7 OncoDNA

    2. *List Not Exhaustive

  7. 7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Competitive Landscape covers- Business Overview, Financials, Products and Strategies and Recent Developments
You Can Purchase Parts Of This Report. Check Out Prices For Specific Sections
Get Price Break-up Now

NTRK Fusion Gene Positive Advanced Solid Tumor Industry Segmentation

NTRK gene fusions involving either NTRK1, NTRK2, or NTRK3 (encoding the neurotrophin receptors TRKA, TRKB, and TRKC, respectively) are oncogenic drivers of various adult and paediatric tumour types. These fusions can be detected in the clinic using a variety of methods, including tumour DNA and RNA sequencing and plasma cell-free DNA profiling. The treatment of patients with NTRK fusion-positive cancers with a first-generation TRK inhibitor, such as larotrectinib or entrectinib, is associated with high response rates.

By Type
By Therapeutics
By Diagnostics
By End-User
Hospitals and Clinics
Cancer Centers
Others
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle-East and Africa
GCC
South Africa
Rest of Middle-East and Africa
South America
Brazil
Argentina
Rest of South America
Need A Different Region Or Segment?
Customize Now

NTRK Fusion Gene Positive Advanced Solid Tumor Market Research FAQs

The NTRK Fusion Gene Positive Advanced Solid Tumor Market is projected to register a CAGR of 5.40% during the forecast period (2024-2029)

Bayer AG , Empire Genomics, LLC, F. Hoffmann-La Roche Ltd. , NeoGenomics Laboratories, Inc. and OncoDNA are the major companies operating in the NTRK Fusion Gene Positive Advanced Solid Tumor Market.

Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029).

In 2024, the North America accounts for the largest market share in NTRK Fusion Gene Positive Advanced Solid Tumor Market.

The report covers the NTRK Fusion Gene Positive Advanced Solid Tumor Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the NTRK Fusion Gene Positive Advanced Solid Tumor Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.

NTRK Fusion Gene Positive Advanced Solid Tumor Industry Report

Statistics for the 2024 NTRK Fusion Gene Positive Advanced Solid Tumor market share, size and revenue growth rate, created by Mordor Intelligenceā„¢ Industry Reports. NTRK Fusion Gene Positive Advanced Solid Tumor analysis includes a market forecast outlook to 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.

NTRK Fusion Gene Positive Advanced Solid Tumor Report Snapshots

close-icon
80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!

NTRK Fusion Gene Positive Advanced Solid Tumor Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)